Trial Profile
A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Cisplatin; Ropidoxuridine
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms REACH
- 03 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2020 Results (n=41) of safety phase with particular focus on skin toxicity published in the European Journal of Cancer
- 22 Sep 2019 According to a Merck KGaA media release, data from the study will be presented at the 2019 European Society for Medical Oncology (ESMO) Congress.